94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Oncol.
Sec. Genitourinary Oncology
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1467579
Case report: An ovarian epithelial type serous adenocarcinoma of testis treated by systemic chemotherapy with bevacizumab referred to its ovarian counterparts
Provisionally accepted- 1 School of Medical and Life Sciences, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan Province, China
- 2 Department of Biotherapy, West China Hospital, Chengdu, Sichuan Province, China
- 3 Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
- 4 Department of Radiology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
- 5 Department of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China
- 6 Cancer Prevention and Treatment Institute of Chengdu, Department of Oncology, Chengdu Fifth People's Hospital, Chengdu, Sichuan Province, China
Ovarian type serous adenocarcinoma of testis is an extremely rare malignant disease, the experience and evidence of its treatment is lack. We describe the case of a 39-year-old man who presented with widespread metastasis in retroperitoneal and pelvic lymph nodes after surgical resection of his right testicular tumor. Systemic chemotherapy with bevacizumab referred to ovarian serous adenocarcinoma was administrated, retroperitoneal lymph node dissection and radiotherapy were following after the lesions' regression. Till now, the patient get a over 3-year progression free survival. This is the first case for application of combination of bevacizumab for this disease, and indicates that bevacizumab may be as an option for the treatment stragety for this rare disease.
Keywords: Ovarian type tumors of testis, Rare tumor, chemotherapy, bevacizumab, case report
Received: 20 Jul 2024; Accepted: 27 Feb 2025.
Copyright: © 2025 Liu, Zhang, Gong, Yao, Zeng and He. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lang He, Cancer Prevention and Treatment Institute of Chengdu, Department of Oncology, Chengdu Fifth People's Hospital, Chengdu, Sichuan Province, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.